Nautilus Biotechnology, Inc. (NAUT): Price and Financial Metrics

Nautilus Biotechnology, Inc. (NAUT): $2.81

0.01 (+0.36%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add NAUT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#291 of 357

in industry

NAUT Price/Volume Stats

Current price $2.81 52-week high $4.65
Prev. close $2.80 52-week low $1.78
Day low $2.72 Volume 29,900
Day high $2.88 Avg. volume 74,832
50-day MA $2.98 Dividend yield N/A
200-day MA $3.04 Market Cap 351.10M

NAUT Stock Price Chart Interactive Chart >


Nautilus Biotechnology, Inc. (NAUT) Company Bio


Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating platform technology for quantifying and unlocking the complexity of the proteome. It operates Nautilus Proteomic Analysis Platform, an integrated single-molecule protein analysis platform that leverages a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to potentially identify and quantify the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington.


NAUT Latest News Stream


Event/Time News Detail
Loading, please wait...

NAUT Latest Social Stream


Loading social stream, please wait...

View Full NAUT Social Stream

Latest NAUT News From Around the Web

Below are the latest news stories about NAUTILUS BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate NAUT as an investment opportunity.

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award

Society award recognizes Dr. Mallick’s decades of innovative leadership and science advancing the field of computational proteomics Parag Mallick, Ph.D. Co-founder and Chief Scientist SEATTLE, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced Nautilus co-founder and Chief Scientist Parag Mallick, Ph.D., was selected as the 2024 recipient of th

Yahoo | November 30, 2023

Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome Martin Huber, Ph.D. Vice President of Biochemistry and Flow Cell Development SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and

Yahoo | November 1, 2023

Nautilus Biotechnology Reports Third Quarter 2023 Financial Results

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023. “I’m very pleased with the progress Nautilus made in Q3 as we continue our drive towards commercial readiness”, said Sujal Patel, CEO of Nautilus. “Continuing to increase the scale and robustness of the platform remains a key area of focus as we rea

Yahoo | October 31, 2023

Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023

SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the we

Yahoo | October 11, 2023

Nautilus Biotechnology to Participate in Upcoming September Investor Conferences

SEATTLE, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference in New York, NYManagement is scheduled to participate in a fireside chat on Wednesday, September 13th at 7:50 a.m. Pacific Time / 10:50 a.m. Eastern Time. Gilmartin Group Emerging Growt

Yahoo | September 6, 2023

Read More 'NAUT' Stories Here

NAUT Price Returns

1-mo -6.02%
3-mo -2.09%
6-mo -11.08%
1-year 56.98%
3-year -82.38%
5-year N/A
YTD -6.02%
2023 66.11%
2022 -65.25%
2021 -52.26%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!